Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Consolidated Net Income: 2014-2025

Historic Consolidated Net Income for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to -$544,000.

  • Zevra Therapeutics' Consolidated Net Income rose 98.36% to -$544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 139.40%. This contributed to the annual value of -$105.5 million for FY2024, which is 129.13% down from last year.
  • Zevra Therapeutics' Consolidated Net Income amounted to -$544,000 in Q3 2025, which was down 100.73% from $74.7 million recorded in Q2 2025.
  • Zevra Therapeutics' Consolidated Net Income's 5-year high stood at $74.7 million during Q2 2025, with a 5-year trough of -$35.7 million in Q4 2024.
  • For the 3-year period, Zevra Therapeutics' Consolidated Net Income averaged around -$7.3 million, with its median value being -$13.2 million (2023).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first spiked by 622.12% in 2021, then crashed by 674.39% in 2024.
  • Zevra Therapeutics' Consolidated Net Income (Quarterly) stood at -$2.7 million in 2021, then skyrocketed by 368.41% to $7.3 million in 2022, then slumped by 374.18% to -$19.9 million in 2023, then tumbled by 79.67% to -$35.7 million in 2024, then spiked by 98.36% to -$544,000 in 2025.
  • Its Consolidated Net Income was -$544,000 in Q3 2025, compared to $74.7 million in Q2 2025 and -$3.1 million in Q1 2025.